{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:02:39Z","timestamp":1783612959094,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.omtm.2023.07.004","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T08:31:45Z","timestamp":1689582705000},"page":"246-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Prevention of early-onset cardiomyopathy in Dmd exon 52\u201354 deletion mice by CRISPR-Cas9-mediated exon skipping"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9257-4102","authenticated-orcid":false,"given":"Matthew","family":"Rok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatianna Wai Ying","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Maino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Hyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Fatehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Delgado-Olgu\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgueni A.","family":"Ivakine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.07.004_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2023.07.004_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.07.004_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2023.07.004_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JND-170280","article-title":"Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database","volume":"4","author":"Koeks","year":"2017","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2023.07.004_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","article-title":"Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"35","author":"Landfeldt","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.omtm.2023.07.004_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"10.1016\/j.omtm.2023.07.004_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","article-title":"The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review","volume":"16","author":"Szabo","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.07.004_bib8","doi-asserted-by":"crossref","first-page":"769896","DOI":"10.3389\/fphar.2021.769896","article-title":"Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study","volume":"12","author":"Raccah","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtm.2023.07.004_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13023-019-1066-9","article-title":"Effect and safety of treatment with ACE-inhibitor Enalapril and \u03b2-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - A randomized, double-blind, placebo-controlled trial","volume":"14","author":"Dittrich","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.07.004_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10654-021-00819-4","article-title":"One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure","volume":"37","author":"Wahlgren","year":"2022","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.omtm.2023.07.004_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omtm.2023.07.004_bib12","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The dystrophin complex: Structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.omtm.2023.07.004_bib13","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.07.004_bib14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1096\/fj.01-0030fje","article-title":"Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury","volume":"15","author":"Danialou","year":"2001","journal-title":"Faseb. J."},{"key":"10.1016\/j.omtm.2023.07.004_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2023.07.004_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: Analysis of more than 7,000 duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2023.07.004_bib17","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.045369","article-title":"A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic DMD deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy","volume":"13","author":"Wong","year":"2020","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2023.07.004_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the correction of muscular dystrophy by gene editing","volume":"118","author":"Olson","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.07.004_bib19","doi-asserted-by":"crossref","first-page":"833833","DOI":"10.3389\/fbioe.2022.833833","article-title":"A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review","volume":"10","author":"Chung Liang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omtm.2023.07.004_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s40778-020-00173-3","article-title":"In\u00a0Vivo Genome Engineering for the Treatment of Muscular Dystrophies","volume":"6","author":"Kustermann","year":"2020","journal-title":"Curr. Stem Cell Rep."},{"key":"10.1016\/j.omtm.2023.07.004_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.07.004_bib22","doi-asserted-by":"crossref","first-page":"859930","DOI":"10.3389\/fmed.2022.859930","article-title":"Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy","volume":"9","author":"Happi Mbakam","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.omtm.2023.07.004_bib23","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1073\/pnas.1613203114","article-title":"Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy","volume":"114","author":"Echigoya","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.07.004_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.07.004_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.07.004_bib27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.07.004_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtm.2023.07.004_bib26","doi-asserted-by":"crossref","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology A decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.omtm.2023.07.004_bib28","series-title":"CRISPR-Cas9 Corrects Duchenne Muscular Dystrophy Exon 44 Deletion Mutations in Mice and Human Cells","author":"Min","year":"2019"},{"key":"10.1016\/j.omtm.2023.07.004_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aap9004","article-title":"Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing","volume":"4","author":"Long","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2023.07.004_bib31","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.07.004_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.omtn.2022.07.024","article-title":"A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing","volume":"29","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.07.004_bib33","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ymthe.2020.05.024","article-title":"Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing","volume":"28","author":"Min","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.07.004_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtm.2023.07.004_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8081","article-title":"Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy","volume":"9","author":"Amoasii","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2023.07.004_bib36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omtm.2023.07.004_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1083\/jcb.201604115","article-title":"CRISPR-Cas9 nuclear dynamics and target recognition in living cells","volume":"214","author":"Ma","year":"2016","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtm.2023.07.004_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124297","article-title":"AAV CRISPR editing rescues cardiac and muscle function for 18\u00a0months in dystrophic mice","volume":"3","author":"Hakim","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2023.07.004_bib39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1089\/hum.2021.130","article-title":"The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy","volume":"33","author":"Wasala","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.07.004_bib40","doi-asserted-by":"crossref","first-page":"eaay6812","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2023.07.004_bib41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.omtm.2021.05.014","article-title":"A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation","volume":"22","author":"Zhang","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.07.004_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.omtn.2022.03.004","article-title":"Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice","volume":"28","author":"Karri","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.07.004_bib43","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1038\/s41467-019-12335-x","article-title":"In\u00a0vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse","volume":"10","author":"Amoasii","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.07.004_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In\u00a0vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtm.2023.07.004_bib45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCRESAHA.117.310996","article-title":"In\u00a0vivo genome editing restores dystrophin expression and cardiac function in dystrophic mice","volume":"121","author":"el Refaey","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.omtm.2023.07.004_bib46","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","article-title":"CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In\u00a0Vitro and In\u00a0Vivo","volume":"26","author":"Duch\u00eane","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.07.004_bib47","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.07.004_bib48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.07.004_bib49","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ymthe.2019.05.001","article-title":"Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.07.004_bib50","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ymthe.2020.11.003","article-title":"Dystrophin Gene-Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles","volume":"29","author":"Bengtsson","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.07.004_bib51","doi-asserted-by":"crossref","first-page":"e13228","DOI":"10.15252\/emmm.202013228","article-title":"Targeted genome editing in\u00a0vivo corrects a Dmd duplication restoring wild-type dystrophin expression","volume":"13","author":"Maino","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2023.07.004_bib52","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ymthe.2021.09.003","article-title":"Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy","volume":"29","author":"Pickar-Oliver","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.07.004_bib53","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1038\/s41467-021-23996-y","article-title":"Efficient precise in\u00a0vivo base editing in adult dystrophic mice","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.07.004_bib54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In\u00a0vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtm.2023.07.004_bib55","series-title":"Long Term Follow-Up after Administration of Human Gene Therapy Products","author":"Fda","year":"2020"},{"key":"10.1016\/j.omtm.2023.07.004_bib56","doi-asserted-by":"crossref","first-page":"1001263","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.07.004_bib57","doi-asserted-by":"crossref","first-page":"809118","DOI":"10.3389\/fmed.2021.809118","article-title":"Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.omtm.2023.07.004_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2023.07.004_bib59","unstructured":"FDA (2021). BRIEFING DOCUMENT Food and Drug Administration (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting #70 Toxicity Risks of Adeno-Associated Virus (AAV) Vectors for Gene Therapy."},{"key":"10.1016\/j.omtm.2023.07.004_bib60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","article-title":"Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy","volume":"26","author":"Moretti","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.07.004_bib61","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2023.07.004_bib62","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1152\/ajpheart.00027.2005","article-title":"Abnormal cardiac inflow patterns during postnatal development in a mouse model of Holt-Oram syndrome","volume":"289","author":"Zhou","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.omtm.2023.07.004_bib63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-019-1430-x","article-title":"A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene","volume":"572","author":"Kemaladewi","year":"2019","journal-title":"Nature"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T01:37:19Z","timestamp":1714786639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":63,"alternative-id":["S2329050123001043"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.07.004","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of early-onset cardiomyopathy in Dmd exon 52\u201354 deletion mice by CRISPR-Cas9-mediated exon skipping","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}